Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Lilly Endowment Inc., a reporting person and director-related holder of Eli Lilly & Co. (LLY) stock, reported multiple open-market sales on 09/30/2025. The Form 4 shows four sell transactions totaling 113,694 shares sold at weighted-average prices of approximately $763.095, $764.355, $765.44, and $766.117, executed across price ranges disclosed in footnotes. After these disposals the reporting person beneficially owned 95,492,993 shares. The filing is signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc., and offers to provide transaction-level price details on request.
Lilly Endowment Inc. reported sales of Eli Lilly & Co. (LLY) common stock on 09/19/2025. The filing shows two dispositions: 22,965 shares sold at a weighted average price of $763.053, and 700 shares sold at a weighted average price of $764.473. Following these transactions the reporting person beneficially owned 95,606,687 shares (direct ownership reported). The form was signed by Diane M. Stenson, Vice President & Treasurer, on 09/22/2025.
Lilly Endowment Inc. reported sales of Eli Lilly & Co. (LLY) common stock on 09/19/2025. The filing shows two dispositions: 22,965 shares sold at a weighted average price of $763.053, and 700 shares sold at a weighted average price of $764.473. Following these transactions the reporting person beneficially owned 95,606,687 shares (direct ownership reported). The form was signed by Diane M. Stenson, Vice President & Treasurer, on 09/22/2025.
Lilly Endowment Inc. reported the sale of 106,626 shares of Eli Lilly & Co. common stock across multiple transactions dated 09/18/2025, reducing its beneficial ownership from 95,697,115 shares to 95,630,352 shares. The Form 4 shows weighted-average sale prices in five tranches with reported averages of approximately $763.292, $764.519, $765.567, $766.451, and $767.065, with underlying per-trade price ranges disclosed in footnotes. The filing identifies the reporting person as Lilly Endowment Inc. (relationship boxes indicate Director and 10% owner) and is signed by Diane M. Stenson on behalf of the endowment.
Lilly Endowment Inc. reported the sale of 106,626 shares of Eli Lilly & Co. common stock across multiple transactions dated 09/18/2025, reducing its beneficial ownership from 95,697,115 shares to 95,630,352 shares. The Form 4 shows weighted-average sale prices in five tranches with reported averages of approximately $763.292, $764.519, $765.567, $766.451, and $767.065, with underlying per-trade price ranges disclosed in footnotes. The filing identifies the reporting person as Lilly Endowment Inc. (relationship boxes indicate Director and 10% owner) and is signed by Diane M. Stenson on behalf of the endowment.
Eli Lilly & Co (LLY) Form 144 notifies the SEC of a proposed sale of 300,000 shares of common stock through J.P. Morgan Securities LLC, listed for sale on 09/18/2025 on NYSE/NASDAQ with an aggregate market value of $228,039,000 out of 946,456,759 shares outstanding. The shares were acquired as a gift on 02/10/1948 from the J.K. Lilly Sr. Trust; the donor originally acquired 38,400,000 shares on 01/21/1937. The filer reports a prior sale in the past three months of 280,000 shares on 07/24/2025 for $225,419,292. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and criminal-warning language.
Eli Lilly & Co (LLY) Form 144 notifies the SEC of a proposed sale of 300,000 shares of common stock through J.P. Morgan Securities LLC, listed for sale on 09/18/2025 on NYSE/NASDAQ with an aggregate market value of $228,039,000 out of 946,456,759 shares outstanding. The shares were acquired as a gift on 02/10/1948 from the J.K. Lilly Sr. Trust; the donor originally acquired 38,400,000 shares on 01/21/1937. The filer reports a prior sale in the past three months of 280,000 shares on 07/24/2025 for $225,419,292. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and criminal-warning language.
Gabrielle Sulzberger, a director of Eli Lilly & Co (LLY), acquired 6.627 shares of the company on 09/15/2025 at a reported price of $748.19 per share. Following the transaction she beneficially owned 2,721.97 shares. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock upon her separation from service.
Gabrielle Sulzberger, a director of Eli Lilly & Co (LLY), acquired 6.627 shares of the company on 09/15/2025 at a reported price of $748.19 per share. Following the transaction she beneficially owned 2,721.97 shares. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock upon her separation from service.
Gabrielle Sulzberger, a director of Eli Lilly & Co (LLY), acquired 6.627 shares of the company on 09/15/2025 at a reported price of $748.19 per share. Following the transaction she beneficially owned 2,721.97 shares. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock upon her separation from service.
Gabrielle Sulzberger, a director of Eli Lilly & Co (LLY), acquired 6.627 shares of the company on 09/15/2025 at a reported price of $748.19 per share. Following the transaction she beneficially owned 2,721.97 shares. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock upon her separation from service.
Juan R. Luciano, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 19.826 shares (reported with a price of $748.19 per share) and indicates 16,455.857 shares beneficially owned following the transaction in a direct ownership form. The filing explains these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service. The Form 4 was signed on behalf of Mr. Luciano on 09/17/2025 by an authorized filer.
Juan R. Luciano, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 19.826 shares (reported with a price of $748.19 per share) and indicates 16,455.857 shares beneficially owned following the transaction in a direct ownership form. The filing explains these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service. The Form 4 was signed on behalf of Mr. Luciano on 09/17/2025 by an authorized filer.
Juan R. Luciano, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 19.826 shares (reported with a price of $748.19 per share) and indicates 16,455.857 shares beneficially owned following the transaction in a direct ownership form. The filing explains these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service. The Form 4 was signed on behalf of Mr. Luciano on 09/17/2025 by an authorized filer.
Juan R. Luciano, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 19.826 shares (reported with a price of $748.19 per share) and indicates 16,455.857 shares beneficially owned following the transaction in a direct ownership form. The filing explains these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock after the reporting person’s separation from service. The Form 4 was signed on behalf of Mr. Luciano on 09/17/2025 by an authorized filer.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
Mary Lynne Hedley, a director of Eli Lilly & Co. (LLY), reported an internal acquisition of common stock on 09/15/2025. The filing shows 2,003.492 shares were acquired and recorded as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares following the reporting person's separation from service. The report lists a per-share amount of $748.19 associated with the transaction. The reporting person disclaims beneficial ownership except to the extent of a pecuniary interest, noting the shares are held by a trust. The Form 4 was signed on behalf of Hedley by Jonathan Groff on 09/17/2025.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported an acquisition on 09/15/2025 of 74,751.392 shares of common stock. The Form 4 lists a per-share price of $748.19. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service. The report is signed on behalf of Fyrwald on 09/17/2025.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported an acquisition on 09/15/2025 of 74,751.392 shares of common stock. The Form 4 lists a per-share price of $748.19. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service. The report is signed on behalf of Fyrwald on 09/17/2025.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported an acquisition on 09/15/2025 of 74,751.392 shares of common stock. The Form 4 lists a per-share price of $748.19. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service. The report is signed on behalf of Fyrwald on 09/17/2025.
J. Erik Fyrwald, a director of Eli Lilly & Co. (LLY), reported an acquisition on 09/15/2025 of 74,751.392 shares of common stock. The Form 4 lists a per-share price of $748.19. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service. The report is signed on behalf of Fyrwald on 09/17/2025.
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Ralph Alvarez, a director of Eli Lilly & Co (LLY), reported a non-derivative acquisition on 09/15/2025. The filing shows an acquisition of 15.705 common stock units at a reported price of $748.19, and after the transaction the reporting person is shown as beneficially owning 55,137.85 shares (direct) and 758 shares indirectly through a trust. The filing discloses these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person’s separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
Edgardo Hernandez, EVP & President, Manufacturing Operations at Eli Lilly & Co. (LLY), reported changes in ownership on a Form 4. On 09/05/2025 he disposed of 17 shares of Eli Lilly common stock in a transaction coded G at a price of $0. After the reported disposition he directly beneficially owned 39,731.435 shares and indirectly held 872.3 shares through a 401(k). No derivative securities were reported. The form was signed on behalf of Mr. Hernandez on 09/08/2025.